Imagine being on the brink of death from tuberculosis (TB), a disease that was once as feared as the bubonic plague. For centuries, TB claimed countless lives, including those of famous figures like Frédéric Chopin and Emily Brontë. But in 1943, a life-saving antibiotic changed everything: streptomycin. Yet, the story behind its discovery has long been shrouded in mystery – until now.
Before streptomycin's arrival, TB was a terrifying disease with few treatment options. Patients often spent months or years in sanatoria, undergoing ineffective remedies like fermented mare's milk [1]. The prognosis was bleak, and the disease had a profound impact on families and communities. Even after the introduction of penicillin in the 1940s, TB remained a formidable foe – until streptomycin came to the rescue.
The first British patients to receive streptomycin were among those who benefited from its miraculous effects [2]. At Clatterbridge General Hospital in Cheshire, a young boy named Peter, suffering from tuberculous meningitis, received the experimental treatment. Doreen Roby, a student nurse, recalled Peter's remarkable recovery: 'We were all amazed as he began to get better – his fever subsided, and he started eating again' [3].
Streptomycin's impact was immediate and far-reaching. The antibiotic saved thousands of lives worldwide and transformed the outlook for TB patients. Yet, as we celebrate this medical breakthrough, it's essential to acknowledge that the true story behind its discovery is more complex than previously thought.
The Nobel Prize awarded in 1952 to Selman A. Waksman, Albert Schatz's professor at Rutgers University, New Jersey, was a historic oversight [4]. The years that followed saw a campaign to correct this injustice and give credit where it's due. Today, the account of Albert Schatz's discovery is being documented and substantiated by those who are fighting for recognition.